November 16, 2023
On November 15, 2023, Astellas Pharma shared a community letter with information on obtaining results for ASP0367 (MA-0211) in Pediatric Male patients with Duchenne muscular dystrophy.
Astellas’ Community Letter can be found by clicking here.
Astellas’ clinical trial study details can be found on their website.
Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org
Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)Â
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
